Ixabepilone Explained

Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is a pharmaceutical drug developed by Bristol-Myers Squibb as a chemotherapeutic medication for cancer.[1]

History

Ixabepilone is a semi-synthetic analog of epothilone B, a natural chemical compound produced by Sorangium cellulosum.[2] Epothilone B itself could not be developed as a pharmaceutical drug because of poor metabolic stability and pharmacokinetics.[3] Ixabepilone was designed through medicinal chemistry to improve upon these properties.[3]

Pharmacology

Much like Taxol, Ixabepilone acts to stabilize microtubules.[4] [5] [6] It is highly potent, capable of damaging cancer cells in very low concentrations, and retains activity in cases where tumor cells are insensitive to taxane type drugs.[7]

Approval

On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies.[8] In November 2008, the EMEA has refused a marketing authorisation for Ixabepilone.[9]

Ixabepilone is administered through injection, and is marketed under the trade name Ixempra.

Clinical uses

Ixabepilone, in combination with capecitabine, has demonstrated effectiveness in the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline and a taxane.[10]

It has been investigated for use in treatment of non-Hodgkin's lymphoma.[11] In pancreatic cancer phase two trial it showed some promising results (used alone). Combination therapy trials are ongoing.[7]

External links

Notes and References

  1. Web site: More information on cancer drugs. www.cancer.org.
  2. Goodin S . Novel cytotoxic agents: epothilones . American Journal of Health-System Pharmacy . 65 . 10 Suppl 3 . S10–S15 . May 2008 . 18463327 . 10.2146/ajhp080089 .
  3. Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G . Preclinical discovery of ixabepilone, a highly active antineoplastic agent . Cancer Chemotherapy and Pharmacology . 63 . 1 . 157–166 . December 2008 . 18347795 . 10.1007/s00280-008-0724-8 . free .
  4. Lopus M, Smiyun G, Miller H, Oroudjev E, Wilson L, Jordan MA . Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype . Cancer Chemotherapy and Pharmacology . 76 . 5 . 1013–1024 . November 2015 . 26416565 . 10.1007/s00280-015-2863-z . 1842156 .
  5. Denduluri N, Swain SM . Ixabepilone for the treatment of solid tumors: a review of clinical data . Expert Opinion on Investigational Drugs . 17 . 3 . 423–435 . March 2008 . 18321240 . 10.1517/13543784.17.3.423 . 71169099 .
  6. Goodin S . Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer . American Journal of Health-System Pharmacy . 65 . 21 . 2017–2026 . November 2008 . 18945860 . 10.2146/ajhp070628 .
  7. Vulfovich M, Rocha-Lima C . Novel advances in pancreatic cancer treatment . Expert Review of Anticancer Therapy . 8 . 6 . 993–1002 . June 2008 . 18533808 . 10.1586/14737140.8.6.993 . 20049942 .
  8. Web site: FDA Approves IXEMPRA(TM) (ixabepilone), A Semi-Synthetic Analog Of Epothilone B, For The Treatment Of Advanced Breast Cancer. Medical News Today.
  9. Web site: European Medicines Agency . Questions and answers on recommendation for the refusal of the marketing authorisation for Ixempra . Doc. Ref. EMEA/602569/2008 . London . 20 November 2008 .
  10. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH . 6 . Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment . Journal of Clinical Oncology . 25 . 33 . 5210–5217 . November 2007 . 17968020 . 10.1200/JCO.2007.12.6557 . free .
  11. Aghajanian C, Burris HA, Jones S, Spriggs DR, Cohen MB, Peck R, Sabbatini P, Hensley ML, Greco FA, Dupont J, O'Connor OA . 6 . Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas . Journal of Clinical Oncology . 25 . 9 . 1082–1088 . March 2007 . 17261851 . 10.1200/JCO.2006.08.7304 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ixabepilone".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.